LOS ANGELES (Reuters) - Continued use of Rituxan cut by about 50 percent the risk that follicular lymphoma patients would have their cancer return, according to a late-stage study of the drug, which ...

Risk factors for relapse after reinduction treatment with rituximab in patients with antineutrophil cytoplasmic ...

The B-cell–depleting drug rituximab was associated with a twofold increased risk for infection in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment duration or ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rituximab and ocrelizumab appeared to increase risk for ...

Please provide your email address to receive an email when new articles are posted on . The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically ...

Modulation of lipid rafts (LR), p-glycoprotein (P-gp) and proinflammatory cytokines (PIC) with HMG-Co A reductase inhibitor simvastatin (SV) in chronic myelogenous leukemia (CML) patients with ...

Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line ...

No patient in the 6-month rituximab group relapsed during the 24-month follow-up, and 1 patient in the 12-month group had a minor relapse. Tailored, risk-stratified rituximab regimens including yearly ...

Although relapse rates were similar across all treatment categories, patients with GPA treated with rituximab monotherapy had a lower relapse risk relative to those on rituximab + cyclophosphamide ...

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®. Treatment with rituximab was associated with more severe COVID-19 infections and ...

Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with ...